Clinical pharmacokinetic profile of modafinil

Clinical Pharmacokinetics

Volumn 42, Issue 2, 2003, Pages 123-137

  Robertson Jr , Philmore ^a   Hellriegel, Edward T ^a  

^a CEPHALON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DEXAMPHETAMINE; DRUG METABOLITE; ETHINYLESTRADIOL; METHYLPHENIDATE; MODAFINIL; MODAFINIL ACID; MODAFINIL SULFONE; NORCLOMIPRAMINE; TRIAZOLAM; UNCLASSIFIED DRUG; WARFARIN;

AGING; ANXIETY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG OXIDATION; ENANTIOMER; ENZYME INDUCTION; ENZYME INHIBITION; HEADACHE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSOMNIA; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MULTIPLE DRUG DOSE; NARCOLEPSY; NAUSEA; NERVOUSNESS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP WAKING CYCLE; STEADY STATE; WAKEFULNESS;

AGED; BENZHYDRYL COMPOUNDS; BIOLOGICAL AVAILABILITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG INTERACTIONS; HUMANS; INTESTINAL ABSORPTION; KIDNEY DISEASES; LIVER DISEASES; NARCOLEPSY; TISSUE DISTRIBUTION;

EID: 0037275524     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200342020-00002     Document Type: Review

References (35)

1. Edgar DM, Seidel WF. Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat. J Pharmacol Exp Ther 1997; 283: 757-69
2. Ferraro L, Antonelli T, O'Connor WT, et al. Modafinil: an antinarcoleptic drug with a different neurochemical profile to damphetamine and dopamine uptake blockers. Biol Psychiatry 1997; 42: 1181-3
3. Simon P, Hemet C, Ramassamy C, et al. Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in mice. Eur Neuropsychopharmacol 1995; 5: 509-14
4. De Sereville JE, Boer C, Rambert FA, et al. Lack of pre-synaptic dopaminergic involvement in modafinil activity in anaesthetized mice: in vivo voltammetry studies. Neuropharmacology 1994; 33: 755-61
5. Mignot E, Nishino S, Guilleminault C, et al. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994; 17: 436-7
6. Lin JS, Roussel B, Akaoka H, et al. Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat. Brain Res 1992; 591: 319-26
7. Akaoka H, Roussel B, Lin JS, et al. Effect of modafinil and amphetamine on the rat catecholaminergic neuron activity. Neurosci Lett 1991; 123: 20-2
8. Engber TM, Dennis SA, Jones BE, et al. Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: comparison with amphetamine. Neuroscience 1998; 87: 905-11
9. Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci U S A 1996; 93: 14128-33
10. Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000; 20: 8620-8
11. Wong YN, King SP, Simcoe D, et al. Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J Clin Pharmacol 1999; 39: 281-8
12. Wong YN, King SP, Laughton WB, et al. Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers. J Clin Pharmacol 1998; 38: 276-82
13. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000; 54: 1166-75
14. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998; 43: 88-97
15. Broughton RJ, Fleming JA, George CF, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997; 49: 444-51
16. Boivin DB, Montplaisir J, Petit D, et al. Effects of modafinil on symptomatology of human narcolepsy. Clin Neuropharmacol 1993; 16: 46-53
17. Bastuji H, Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12: 695-700
18. McClellan KJ, Spencer CM. Modafinil: a review of its pharmacology and clinical efficacy in the management of narcolepsy. CNS Drugs 1998; 9: 311-24
19. Gorman SH. Determination of the d- and l-enantiomers of modafinil in human plasma utilizing liquid-liquid extraction and high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1999; 730: 1-7
20. Gorman SH. Determination of modafinil, modafinil acid, and modafinil sulfone in human plasma utilizing liquid-liquid extraction and high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 767: 269-76
21. Burnat P, Robles F, Do B. High-performance liquid chromatographic determination of modafinil and its two metabolites in human plasma using solid-phase extraction. J Chromatogr B Biomed Sci Appl 1998; 706: 295-304
22. Moachon G, Matinier D. Simultaneous determination of modafinil and its acid metabolite by high-performance liquid chromatography in human plasma. J Chromatogr B Biomed Appl 1994; 654: 91-6
23. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982
24. Moachon G, Kanmacher I, Clenet M, et al. Pharmacokinetic profile of modafinil. Drugs Today 1996; 32: 327-37
25. Wong YN, Simcoe D, Hartman LN, et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 1999; 39: 30-40
26. Wong YN, Wang L, Hartman L, et al. Comparison of the single-dose pharmacokinetics and tolerability of modafinil and dextroamphetamine administered alone or in combination in healthy male volunteers. J Clin Pharmacol 1998; 38: 971-8
27. Hellriegel ET, Arora S, Nelson M, et al. Steady-state pharmacokinetics and tolerability of modafinil given alone or in combination with methylphenidate in healthy volunteers. J Clin Pharmacol 2001; 41: 895-904
28. Hellriegel ET, Arora S, Nelson M, et al. Steady-state pharmacokinetics and tolerability of modafinil administered alone or in combination with dextroamphetamine in healthy volunteers. J Clin Pharmacol 2002; 42: 450-60
29. Robertson P, Hellriegel ET, Arora S, et al. Effect of modafinil at steady state on the single-dose pharmacokinetic profile of warfarin in healthy volunteers. J Clin Pharmacol 2002; 42: 205-14
30. Robertson P, Hellriegel ET, Arora S, et al. Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers. Clin Pharmacol Ther 2002; 71: 46-56
31. Durnas C, Loi CM, Cusack BJ. Hepatic drug metabolism and aging. Clin Pharmacokinet 1990; 19: 359-89
32. Schmucker DL. Aging and drug disposition: an update. Pharmacol Rev 1985; 37: 133-48
33. Robertson P, DeCory HH, Madan A, et al. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab Dispos 2000; 28: 664-71
34. Le Cacheux P, Charasse C, Mourtada R, et al. Gelineau syndrome in a patient with renal transplantation: evidence of cyclosporine-modafinil interaction [letter]. Presse Med 1997; 26: 466
35. Grözinger M, Hartter S, Hiemke C, et al. Interaction of modafinil and clomipramine as comedication in a narcoleptic patient. Clin Neuropharmacol 1998; 21: 127-9